Matthew Biegler
Stock Analyst at Oppenheimer
(3.59)
# 849
Out of 5,090 analysts
86
Total ratings
38.16%
Success rate
10.82%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AAPG Ascentage Pharma Group International | Initiates: Outperform | $45 | $32.88 | +36.86% | 1 | Dec 4, 2025 | |
| OLMA Olema Pharmaceuticals | Maintains: Outperform | $22 → $45 | $27.21 | +65.38% | 8 | Nov 18, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $12 → $15 | $11.00 | +36.36% | 6 | Nov 14, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Maintains: Outperform | $23 → $22 | $13.69 | +60.70% | 2 | Nov 13, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $30 → $28 | $18.09 | +54.78% | 3 | Oct 10, 2025 | |
| ACRV Acrivon Therapeutics | Maintains: Outperform | $9 → $8 | $2.37 | +237.55% | 4 | Aug 14, 2025 | |
| CTMX CytomX Therapeutics | Initiates: Outperform | $7 | $3.95 | +77.22% | 1 | Jul 31, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $10 → $9 | $1.43 | +529.37% | 2 | May 14, 2025 | |
| VOR Vor Biopharma | Reiterates: Outperform | $160 | $8.18 | +1,855.99% | 7 | Mar 21, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $40 → $45 | $12.79 | +251.84% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $105 → $115 | $121.22 | -5.13% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $53 | $35.87 | +47.76% | 5 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $33 | $21.50 | +53.49% | 6 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $1.39 | +1,338.85% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $7.68 | - | 6 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $6.88 | - | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $8.90 | +57.30% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $8.00 | - | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.08 | - | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $7.92 | - | 2 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.80 | - | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.98 | - | 2 | Dec 22, 2022 |
Ascentage Pharma Group International
Dec 4, 2025
Initiates: Outperform
Price Target: $45
Current: $32.88
Upside: +36.86%
Olema Pharmaceuticals
Nov 18, 2025
Maintains: Outperform
Price Target: $22 → $45
Current: $27.21
Upside: +65.38%
ORIC Pharmaceuticals
Nov 14, 2025
Maintains: Outperform
Price Target: $12 → $15
Current: $11.00
Upside: +36.36%
BridgeBio Oncology Therapeutics
Nov 13, 2025
Maintains: Outperform
Price Target: $23 → $22
Current: $13.69
Upside: +60.70%
Nurix Therapeutics
Oct 10, 2025
Maintains: Outperform
Price Target: $30 → $28
Current: $18.09
Upside: +54.78%
Acrivon Therapeutics
Aug 14, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $2.37
Upside: +237.55%
CytomX Therapeutics
Jul 31, 2025
Initiates: Outperform
Price Target: $7
Current: $3.95
Upside: +77.22%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $10 → $9
Current: $1.43
Upside: +529.37%
Vor Biopharma
Mar 21, 2025
Reiterates: Outperform
Price Target: $160
Current: $8.18
Upside: +1,855.99%
Arvinas
Feb 12, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $12.79
Upside: +251.84%
Dec 10, 2024
Reiterates: Outperform
Price Target: $105 → $115
Current: $121.22
Upside: -5.13%
Oct 29, 2024
Reiterates: Outperform
Price Target: $53
Current: $35.87
Upside: +47.76%
Sep 19, 2024
Maintains: Outperform
Price Target: $25 → $33
Current: $21.50
Upside: +53.49%
Sep 16, 2024
Reiterates: Outperform
Price Target: $20
Current: $1.39
Upside: +1,338.85%
Sep 10, 2024
Downgrades: Perform
Price Target: n/a
Current: $7.68
Upside: -
Jul 2, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $6.88
Upside: -
May 14, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $8.90
Upside: +57.30%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $8.00
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.08
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $7.92
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.80
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.98
Upside: -